Edwards Lifesciences Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2022
For the full year, the company expects sales to grow at a low double-digit underlying rate to be between $5.5 billion to $6.0 billion, which includes an estimated negative year-over-year impact of $170 million from foreign exchange.